GlobeNewswire Inc.T3·9d ago
EIKN Eikon Therapeutics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
EIKN
—
—
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 384
- List Date
- 2026-02-05
- CIK
- 0001861123
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($1.74)
- Headquarters
- Millbrae, CA
- Homepage
- https://www.eikontx.com
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | -8.13% | -8.13% |
| Mar | -28.90% | -28.90% |
| Apr | -4.61% | -4.61% |
| May | 11.98% | 11.98% |
| Jun | 20.95% | 20.95% |
| Jul | -25.30% | -25.30% |
| Aug | 14.32% | 14.32% |
| Sep | -26.10% | -26.10% |
| Oct | -28.34% | -28.34% |
| Nov | 12.50%* | 12.50% |
| Dec | -- | -- |
| Total | -57.07% | -57.07% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.76
SMA 50: $8.24
SMA 200: —
Current: $6.39
EMA 12: $6.21
EMA 26: $6.92
MACD: -0.7064 | Signal: -0.0299
BEARISH
ADX (14): 25.38
TREND
+DI: 20.10
−DI: 27.35
Momentum Oscillators
RSI (14): 43.89
NEUTRAL
Stoch %K: 24.92
Stoch %D: 16.50
Williams %R: -60.17
Volume & Volatility
BB Upper: $8.79
BB Lower: $4.73
NEUTRAL
OBV: 7,577,949
Vol SMA 20: 527,040
Vol ROC: 173.95%
ATR: $0.70
True Range: $1.06
HV 20: 133.6%
HV 30: 112.0%
HV 60: 104.7%
Data Summary
Data Points: 189
Last Updated:
Date Range: 2026-02-05T00:00:00 – 2026-11-04T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All EIKN news →
GlobeNewswire Inc.T3·17d ago
GlobeNewswire Inc.T3·5mo ago
EIKN Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.9277
Alpha: -103.59%
Correlation: 0.2738
R-Squared: 7.5%
Stock Volatility: 93.7%
Market Volatility: 13.3%
Analysis Details
Benchmark: SPY
Data Points: 188
Period: 252 trading days
Data Points: 188
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own EIKN
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $1.7M | #2651 of 3716 | -24.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $350K | #2726 of 3138 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $170K | #5568 of 6285 | -95.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
EIKN Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
EIKN Insider Trading (Form 4)
Latest: 2026-09-08Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Column Group IV-A, LP | 10%+ Owner | Buy (P) | +89,200 | $11.56 | $1.03M | EDGAR |
| 2026-03-04 | Michael A Klobuchar | Chief Operating Officer | Grant (A) | +87,157 opt | — | EDGAR | |
| 2026-03-04 | Robert Luther Huffines | Director | Grant (A) | +25,873 opt | — | EDGAR | |
| 2026-03-04 | Alfred Lloyd Bowie Jr. | Chief Financial Officer | Grant (A) | +67,044 opt | — | EDGAR | |
| 2026-03-04 | Roy D. Baynes | Chief Medical Officer | Grant (A) | +134,088 opt | — | EDGAR | |
| 2026-03-04 | Kenneth C Frazier | Director | Grant (A) | +25,873 opt | — | EDGAR | |
| 2026-03-04 | Roger M Perlmutter | See remarks | Grant (A) | +268,176 opt | — | EDGAR | |
| 2026-03-04 | Benjamin Bruno Thorner | See Remarks | Grant (A) | +67,044 opt | — | EDGAR | |
| 2026-02-10 | Roger M Perlmutter | See remarks | Conv (C) | +284,857 | — | EDGAR | |
| 2026-02-09 | TCG Opportunity III GP, LLC | 10%+ Owner | Mixed | +5,713,100 | $18.00 | $38.12M | EDGAR |
| 2026-02-06 | Kenneth C Frazier | Director | Buy (P) | +111,111 | $18.00 | $2.00M | EDGAR |
| 2026-02-06 | Josh Wolfe | Director | Mixed | +5,972,786 | $18.00 | $5.00M | EDGAR |
| 2026-02-06 | Lux Ventures V, L.P. | 10%+ Owner | Mixed | +5,972,786 | $18.00 | $5.00M | EDGAR |
| 2026-02-06 | Foresite Capital VI-A, LLC | 10%+ Owner | Mixed | +4,097,242 | $18.00 | $1000.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
EIKN Insider Holdings
7 insiders · @ $6.39
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lux Ventures V, L.P. | 10%+ Owner | 2,387,705 | $15.26M | $5.00M | 1 | 2026-02-06 |
| 2 | TCG Opportunity III GP, LLC | 10%+ Owner | 1,360,320 | $8.69M | $38.12M | 1 | 2026-02-09 |
| 3 | Foresite Capital VI-A, LLC | 10%+ Owner | 737,366 | $4.71M | $1000.0K | 1 | 2026-02-06 |
| 4 | Roger M Perlmutter | See remarks | 284,857 | $1.82M | $0 | 2 | 2026-03-04 |
| 5 | Column Group IV-A, LP | 10%+ Owner | 148,840 | $951.1K | $1.03M | 1 | 2026-09-08 |
| 6 | Josh Wolfe | Director | 138,888 | $887.5K | $5.00M | 1 | 2026-02-06 |
| 7 | Kenneth C Frazier | Director | 111,111 | $710.0K | $2.00M | 2 | 2026-03-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
EIKN Board & Officers
As of SEC filings through Sep 8, 2026Directors 7
- David W Meline · since Feb 4, 2026
- Josh Wolfe · since Feb 4, 2026
- Kenneth C Frazier · since Feb 4, 2026
- Leon Chen · since Feb 4, 2026
- Robert Luther Huffines · since Feb 4, 2026
- Roger M Perlmutter · since Feb 4, 2026
- Ma. Fatima Francisco · since Jun 15, 2026
Officers 5
- Roger M Perlmutter · Chief Executive Officer and Director · since Feb 4, 2026
- Alfred Lloyd Bowie Jr. · Chief Financial Officer · since Feb 4, 2026
- Michael A Klobuchar · Chief Operating Officer · since Feb 4, 2026
- Benjamin Bruno Thorner · General Counsel and Chief Business Officer · since Feb 4, 2026
- Roy D. Baynes · Chief Medical Officer · since Feb 4, 2026
10% owners 14
- Column Group IV GP, LP (entity) · since Feb 4, 2026
- Column Group IV, LP (entity) · on file since Feb 2026
- Column Group IV-A, LP (entity) · since Feb 4, 2026
- Column Group Opportunity III GP, LP (entity) · since Feb 4, 2026
- Column Group Opportunity III, LP (entity) · since Feb 4, 2026
- Josh Wolfe · since Feb 4, 2026
- Lux Co-Invest Opportunities II, L.P. (entity) · since Feb 4, 2026
- Lux Total Opportunities, L.P. (entity) · since Feb 4, 2026
- Lux Venture Partners V, LLC (entity) · since Feb 4, 2026
- Lux Ventures V, L.P. (entity) · since Feb 4, 2026
- Peter Hebert · since Feb 4, 2026
- Peter Svennilson · on file since Feb 2026
- TCG Opportunity III GP, LLC (entity) · since Feb 4, 2026
- Tim Kutzkey · on file since Feb 2026
Changes in the last 10 years (42)
| Jun 15, 2026 | Ma. Fatima Francisco became a director |
| Feb 9, 2026 | Tim Kutzkey first on file as a 10% owner |
| Feb 9, 2026 | Peter Svennilson first on file as a 10% owner |
| Feb 9, 2026 | Column Group IV, LP first on file as a 10% owner |
| Feb 6, 2026 | Foresite Capital VI-A, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2026 | Foresite Capital VI-A Management, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2026 | Foresite Capital Opportunity Management V, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2026 | Foresite Capital Opportunity Fund V, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2026 | Foresite Capital Management V, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2026 | Foresite Capital Management IV, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2026 | Foresite Capital Fund V, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 6, 2026 | Foresite Capital Fund IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 4, 2026 | TCG Opportunity III GP, LLC became a 10% owner |
| Feb 4, 2026 | Roy D. Baynes became Chief Medical Officer |
| Feb 4, 2026 | Roger M Perlmutter became a director |
| Feb 4, 2026 | Roger M Perlmutter became Chief Executive Officer and Director |
| Feb 4, 2026 | Robert Luther Huffines became a director |
| Feb 4, 2026 | Peter Hebert became a 10% owner |
| Feb 4, 2026 | Michael A Klobuchar became Chief Operating Officer |
| Feb 4, 2026 | Lux Ventures V, L.P. became a 10% owner |
| Feb 4, 2026 | Lux Venture Partners V, LLC became a 10% owner |
| Feb 4, 2026 | Lux Total Opportunities, L.P. became a 10% owner |
| Feb 4, 2026 | Lux Co-Invest Opportunities II, L.P. became a 10% owner |
| Feb 4, 2026 | Leon Chen became a director |
| Feb 4, 2026 | Kenneth C Frazier became a director |
| Feb 4, 2026 | Josh Wolfe became a director |
| Feb 4, 2026 | Josh Wolfe became a 10% owner |
| Feb 4, 2026 | Foresite Capital VI-A, LLC became a 10% owner |
| Feb 4, 2026 | Foresite Capital VI-A Management, LLC became a 10% owner |
| Feb 4, 2026 | Foresite Capital Opportunity Management V, LLC became a 10% owner |
| Feb 4, 2026 | Foresite Capital Opportunity Fund V, L.P. became a 10% owner |
| Feb 4, 2026 | Foresite Capital Management V, LLC became a 10% owner |
| Feb 4, 2026 | Foresite Capital Management IV, LLC became a 10% owner |
| Feb 4, 2026 | Foresite Capital Fund V, L.P. became a 10% owner |
| Feb 4, 2026 | Foresite Capital Fund IV, L.P. became a 10% owner |
| Feb 4, 2026 | David W Meline became a director |
| Feb 4, 2026 | Column Group Opportunity III, LP became a 10% owner |
| Feb 4, 2026 | Column Group Opportunity III GP, LP became a 10% owner |
| Feb 4, 2026 | Column Group IV-A, LP became a 10% owner |
| Feb 4, 2026 | Column Group IV GP, LP became a 10% owner |
| Feb 4, 2026 | Benjamin Bruno Thorner became General Counsel and Chief Business Officer |
| Feb 4, 2026 | Alfred Lloyd Bowie Jr. became Chief Financial Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
27 ETFs hold EIKN
25 shown · $19.02M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $5.3M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $4.5M | $75.8B | 2026-11-02 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.7M | — | 2026-09-30 |
| 4 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.5M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $1.2M | $13.9B | 2026-11-02 |
| 6 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $1.1M | — | 2026-05-31 |
| 7 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.29% | $700,789 | — | 2026-08-31 |
| 8 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.05% | $554,090 | $1.2B | 2026-11-02 |
| 9 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $515,352 | $14.1B | 2026-11-02 |
| 10 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Invesco | 0.08% | $221,991 | — | 2026-11-03 |
| 11 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.01% | $192,558 | — | 2026-09-30 |
| 12 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $168,627 | — | 2026-05-31 |
| 13 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $85,359 | — | 2026-11-03 |
| 14 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $74,828 | — | 2026-09-30 |
| 15 | TMED T. Rowe Price Health Care ETF | Nport | 0.31% | $72,062 | — | 2026-06-30 |
| 16 | TINY ProShares Nanotechnology ETF | ProShares | 0.58% | $65,113 | — | 2026-11-03 |
| 17 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.01% | $40,543 | — | 2026-08-31 |
| 18 | AVUS Avantis U.S. Equity ETF | Avantis | 0.00% | $34,818 | $14.6B | 2026-11-02 |
| 19 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $24,643 | — | 2026-09-30 |
| 20 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $10,018 | — | 2026-11-03 |
| 21 | BMED iShares Health Innovation Active ETF | iShares (BlackRock) | 0.05% | $7,907 | $14.5M | 2026-11-02 |
| 22 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $7,792 | — | 2026-11-03 |
| 23 | KBFR Innovator U.S. Small Cap Managed 10 Buffer ETF | Innovator | 0.05% | $6,421 | $13.4M | 2026-11-03 |
| 24 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $5,467 | — | 2026-11-03 |
| 25 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $222 | — | 2026-11-03 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.